MedPath

Agaricus Bisporus and Influenza Vaccination Response

Not Applicable
Completed
Conditions
Immune Response
Interventions
Dietary Supplement: Agaricus bisporus capsules
Dietary Supplement: Control capsules
Registration Number
NCT06041867
Lead Sponsor
Maastricht University Medical Center
Brief Summary

There are numerous in vitro and animal studies that suggested that mushrooms beneficially influence the immune system. We have recently shown that a wild isolate of the edible Agaricus bisporus mushroom had a clear effect on parameters reflecting a better function of the immune system, both in vitro and in vivo in animals. The question now is whether this efficacy can also be translated to humans. In humans, measuring the antibody response is the golden standard to evaluate immune function. If Agaricus bisporus powder indeed has beneficial effects on the immune system, people with overweight or obesity and higher age might benefit from consuming Agaricus bisporus powder prior to receiving the influenza vaccination.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
88
Inclusion Criteria
  • Aged 60 years or older during influenza season 2023/2024 (in line with RIVM guidelines)
  • BMI between 20 and 35 kg/m2
  • Willing to abstain from mushrooms other than the capsules containing a mushroom powder as provided by us during the study period.
  • Willing to keep the intake of fish oil, Zinc, Selenium and (vitamin) supplements constant
  • Willing to abstain from products / supplements enriched with Vitamin D
  • Willing to abstain from products / supplements enriched with plant sterols or stanols
  • Willing to abstain from products / supplements enriched with (β)glucans or fungi.
  • Willing to abstain from products / supplements that are mentioned to "boost your immune system"
  • Willing to abstain from (products enriched in) pre/pro-biotics
  • Willing to abstain from products/supplements enriched with ergothioneine
Exclusion Criteria
  • Already received influenza vaccination in 2023
  • Allergy to mushrooms
  • Known allergic reaction to an active component or other components of the vaccine (e.g. Chicken Eggs)
  • Having donated blood within one month prior to the start of the study, or planning to donate blood during the study
  • Excessive alcohol use (>20 consumptions per week)
  • Regular use of soft and/or hard drugs
  • Using medication for diseases known to affect inflammation/immunity (e.g. inhaled corticosteroids and prednisone)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo groupInfluenza vaccineDietary supplement: 10 placebo capsules, capsules that do not contain Agaricus bisporus powder
Agaricus bisporus groupAgaricus bisporus capsulesDietary supplement: 10 capsules containing 500 mg Agaricus bisporus powder each
Agaricus bisporus groupInfluenza vaccineDietary supplement: 10 capsules containing 500 mg Agaricus bisporus powder each
Placebo groupControl capsulesDietary supplement: 10 placebo capsules, capsules that do not contain Agaricus bisporus powder
Primary Outcome Measures
NameTimeMethod
Vaccine specific antibody titerTime Frame: Differences in influenza specific antibody titers at any measured time point ((Day=0 (day before vaccination), weekly in the month after vaccination (week 1, week 2, week 3 and week 4 after vaccination))

The response to the Influenza vaccine will be measured by quantifying the specific antibody titer

Secondary Outcome Measures
NameTimeMethod
Diary outcomes (2)Day - 1 (start study), T=4 weeks after vaccination (end of study)

Medication intake as assessed by the diary

Anthropometry (4)Day - 1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

Hip circumference

Anthropometry (5)Day - 1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

Waist-to-hip ratio

Diary outcomes (1)Day - 1 (start study), T=4 weeks after vaccination (end of study)

Adverse events as assessed by the diary

Fasted metabolism (1)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Serum non-cholesterol sterols and stanols

Fasted metabolism (2)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Serum lipid and lipoprotein profile

Anthropometry (2)Day -1 (start study)

Height

Quality of life questionnaireDay - 1 (start study), T=4 weeks after vaccination (end of study)

Quality of life questionnaire is used to determine the participants overall wellbeing and quality of life

Immune parameters (1)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Cytokine production by PBMCs after stimulation with antiCD3-antiCD28 antiCD28 antibodies using the TruCulture system

Leukocyte countDay - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Number of leukocytes measured in EDTA plasma

Leukocyte differential countDay - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Number of subgroups of leukocytes measured in EDTA plasma

Fasted metabolism (5)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Glutathione

Fasted metabolism (3)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Plasma glucose

Anthropometry (1)Day - 1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

Body weight

Anthropometry (3)Day - 1 (start study), T=0 (day before vaccination), weekly in the month after vaccination (T1-T4)

Waist circumference

Immune parameters (2)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

hsCRP

Fasted metabolism (4)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Ergothioneine

Fasted metabolism (6)Day - 1 (start study), T=0 (day before vaccination), T=4 weeks after vaccination (end of study)

Malondialdehyde

DietDay - 1 (start study), T=4 weeks after vaccination (end of study)

Food frequency questionnaire is used to determine if the participants maintain their habitual diet and to determine if the participants do not consume mushrooms outside the intervention

Trial Locations

Locations (1)

Maastricht University Medical Center

🇳🇱

Maastricht, Limburg, Netherlands

© Copyright 2025. All Rights Reserved by MedPath